Compensation award — excluded from discretionary-purchase analysis.
Traded Jan 5, 2026 · Filed Jan 6, 2026
A board member of Halozyme sold $141K of Halozyme shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$140,500
Shares × reported transaction price
63 days after results of Nov 3, 2025, 23 days before results of Jan 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.9% | +0.1% | −3.0% |
| 30 days | +8.2% | +0.1% | +8.0% |
| 90 days | −15.3% | −4.4% | −10.9% |
| 180 days | +7.5% | +8.9% | −1.4% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.